PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 8, 2025Acta Paediatrica

The Safety and Efficacy of Anti‐Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity

View Full Paper
Ask AI
Bookmark
Share

Authors

ETElektra TsivitanidouASAbdullah ShakeelOWOmar Warda

Discussion

Loading...

Member takes

Overview

Systematic review reveals biosimilars improve clinical outcomes in preterm infants with retinopathy, suggesting safety and efficacy profiles warrant further randomized controlled trials.

Key Points

  • Biosimilars showed safety with an adverse event rate of just 0.5%, confirming their potential for wider use.
  • Treatment success rates reached 65% for bevacizumab biosimilars in the cohort of 382 eyes analyzed across five studies.
  • The analysis of intravitreal administration methods through random forest plots compared outcomes from two types of biosimilars.
  • Biosimilars provide a cost-effective alternative, highlighting the need for randomized controlled trials against their reference biologics.

Cite This Study

Tsivitanidou et al. (2025) studied this question.

synapsesocial.com/papers/693624a44fa91c937236c2f1https://doi.org/10.1111/apa.70400
View Full Paper
Ask AI
Bookmark
Share